Novartis Fabhalta wins first FDA traditional approval to slow IgAN kidney decline

Novartis AG (NYSE: NVS; SIX: NOVN) has received United States Food and Drug Administration (FDA) traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy at risk of disease progression. The approval, announced on 17 July 2026, upgrades a previous accelerated approval granted in August 2024 for the reduction of proteinuria, and makes Fabhalta the first and only complement inhibitor with a full label claim on preserving kidney function in primary IgA nephropathy. The decision arrived under priority review, one day before Novartis is scheduled to publish its second-quarter 2026 results, and ten days after Vera Therapeutics, Inc. (Nasdaq: VERA) received accelerated approval for Trutakna (atacicept-vymj) in the same indication. The central tension is whether Novartis has secured a durable regulatory and commercial lead in primary IgA nephropathy, or simply widened the first phase of a competitive race that now includes complement inhibitors, endothelin receptor antagonists and B-cell targeted therapies.

Why does FDA traditional approval matter more than the 2024 accelerated approval for Fabhalta commercial positioning?

The distinction between accelerated and traditional approval is central to how Fabhalta can be sold, prescribed and reimbursed in the United States. Accelerated approval, granted in August 2024, allowed Novartis to market Fabhalta based on a reduction in proteinuria, which is considered a surrogate marker for kidney damage in primary IgA nephropathy. That earlier authorisation was conditional and had to be confirmed by outcomes data showing clinical benefit.

Traditional approval removes that conditionality. The FDA has now accepted that Fabhalta slows the decline in estimated glomerular filtration rate, the direct measure of kidney function used by clinicians to judge disease progression. That reclassification changes the promotional and clinical conversation because eGFR decline is the outcome most closely linked to eventual dialysis or transplantation.

The label upgrade also has practical consequences beyond marketing. Payers and pharmacy benefit managers generally treat drugs with confirmed clinical outcomes data differently from those approved on surrogate endpoints. It becomes harder to argue that a therapy should be restricted to narrow subgroups, or subject to step-therapy requirements, once the regulator has accepted that it protects kidney function itself.

Fabhalta remains subject to a Risk Evaluation and Mitigation Strategy programme because the drug increases the risk of serious infections from encapsulated bacteria. Patients must be vaccinated before treatment. That is a real commercial friction point, but it is now applied to a fully approved disease-modifying therapy rather than a conditionally approved proteinuria treatment. The stronger label makes those infrastructure requirements easier to justify to prescribers.

What did the APPLAUSE-IgAN eGFR data actually show and how robust is the 48% claim?

The traditional approval was supported by the Phase III APPLAUSE-IgAN study. Novartis reported that Fabhalta produced an annualised mean change from baseline in estimated glomerular filtration rate of negative 3.0 millilitres per minute per 1.73 square metres per year, compared with negative 5.7 for placebo. That is the arithmetic basis for the 48% slowing of kidney function decline referenced in the company’s announcement.

The figures reflect two years of follow-up data. Clinically meaningful reductions in proteinuria were observed as early as two weeks, with the reduction sustained through the treatment period. Novartis said Fabhalta consistently outperformed placebo across the key kidney outcomes assessed in the study.

The most common adverse events reported were abdominal pain, dizziness and nausea, which the company described as consistent with the previously reported safety profile. The absence of new safety signals matters because complement inhibitors are used in chronic dosing across other rare diseases, and any new tolerability concern would have complicated the label.

Investors should nevertheless treat the 48% figure with the usual caution about surrogate-to-outcome translation. Two years of eGFR preservation is a strong indicator of long-term kidney function benefit, but progression to dialysis or transplantation typically develops over 10 to 20 years in patients with persistent proteinuria. The clinical case for Fabhalta will continue to strengthen only if longer-term data confirm that the initial slope of eGFR decline translates into fewer end-stage kidney events.

That is the level of proof that also allows Novartis to build a differentiated commercial narrative against products still limited to proteinuria endpoints.

How does Fabhalta now compare with Vera Therapeutics Trutakna after the FDA decision?

The proximity of the two approvals is unusually close. Vera Therapeutics received accelerated approval for Trutakna on 7 July 2026, ten days before the Fabhalta upgrade. Trutakna is indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression, and the label explicitly states that it has not been established whether the drug slows kidney function decline over the long term.

That is the key regulatory contrast. Trutakna is currently sold on the same type of surrogate-endpoint label that Fabhalta held between August 2024 and 17 July 2026. Vera Therapeutics has said it plans to submit a supplemental Biologics License Application for full approval in the fourth quarter of 2026, pending results of a revised eGFR analysis from the ORIGIN 3 trial expected in the third quarter.

Novartis has therefore reached the disease-modifying label first. That advantage is real but not permanent. If Vera Therapeutics reports strong eGFR data and successfully secures full approval, the two therapies will compete more directly on mechanism, delivery, safety burden and price.

The mechanistic difference is meaningful. Fabhalta is an oral Factor B inhibitor targeting the alternative complement pathway. Trutakna is a once-weekly subcutaneous injection delivered through an autoinjector, and is described by Vera Therapeutics as the first and only inhibitor of both B-cell activating factor and a proliferation-inducing ligand.

Fabhalta’s oral administration is attractive for chronic use, but the REMS programme and vaccination requirements create real onboarding steps. Trutakna’s cleaner label is easier for prescribers to initiate but requires weekly self-injection. Neither profile is obviously dominant, which is why the eGFR data from ORIGIN 3 will be the decisive competitive event of the coming quarters.

Why does Novartis need Vanrafia and zigakibart alongside Fabhalta to build a durable IgAN franchise?

Novartis is deliberately building a portfolio rather than relying on a single asset. Alongside Fabhalta, the company markets Vanrafia (atrasentan), an oral endothelin receptor antagonist approved for use in primary IgA nephropathy, and is developing zigakibart, an investigational APRIL inhibitor.

The strategic logic reflects the heterogeneity of primary IgA nephropathy. Patients differ in their disease drivers, degree of proteinuria, rate of eGFR decline and response to available therapies. A single mechanism is unlikely to serve every patient, and clinical guideline updates from Kidney Disease Improving Global Outcomes now recognise multiple mechanisms of disease progression.

A portfolio also protects against direct substitution risk. If Trutakna, or another entrant such as Otsuka’s Voyxact or a future Vertex Pharmaceuticals candidate, captures share in one segment, Novartis can retain patients through combination or sequential use of its other IgA nephropathy therapies. Physicians increasingly want the option to layer complement, endothelin and B-cell targeted mechanisms, and Novartis is positioning itself as the only company with active commercial or late-stage assets across all three.

The commercial risk is that portfolio breadth increases promotional complexity and sales-force cost. Each therapy requires distinct clinical education, safety monitoring and reimbursement pathways. Novartis must show that the incremental revenue and defensive value of the portfolio approach exceeds the additional operational cost of supporting multiple launches.

The Fabhalta traditional approval strengthens the anchor of that portfolio. It provides Novartis with the strongest possible label to lead physician conversations, before layering in Vanrafia for endothelin-driven progression or reserving zigakibart for future launch.

How commercially significant is the REMS burden and $10 patient pricing for Fabhalta uptake?

Novartis said nearly 100 percent of United States patients pay 10 dollars or less per month for Fabhalta through its access programmes. That is a substantial commitment for a specialty medication in a rare kidney disease, and it directly addresses one of the biggest historical barriers to complement-inhibitor uptake in the United States.

Rare disease drugs frequently carry list prices in six figures on an annualised basis. Even with insurance, patient out-of-pocket exposure can prevent initiation or lead to premature discontinuation. Novartis has effectively removed that variable for the vast majority of eligible patients, provided they can access the company’s support programmes.

The REMS programme is the counterweight. Iptacopan blocks part of the alternative complement pathway, which increases patient risk of serious infections from encapsulated bacteria such as Neisseria meningitidis, Streptococcus pneumoniae and Haemophilus influenzae type b. Patients must be vaccinated before starting treatment, and prescribers must be enrolled in the REMS system.

For nephrologists managing patients with chronic autoimmune disease, this is not an unfamiliar workflow. Complement inhibitors are already used in paroxysmal nocturnal haemoglobinuria and other rare conditions with similar risk profiles. However, the vaccination step introduces a delay between diagnosis and initiation that competitors without REMS obligations will not face.

Trutakna, by contrast, does not carry an equivalent REMS requirement. If Vera Therapeutics maintains that operational simplicity through its own launch, it could win share with prescribers who prioritise time to treatment or work in less specialised settings. Novartis will need to demonstrate that the strength of the traditional approval label offsets the practical friction of REMS-based initiation.

What is the size of the primary IgAN commercial opportunity that Novartis is now targeting?

Primary IgA nephropathy is a chronic autoimmune kidney disease with meaningful epidemiological reach. Novartis said approximately 25 people per million are newly diagnosed each year worldwide. Up to 50 percent of patients with persistent proteinuria progress to kidney failure within 10 to 20 years of diagnosis, often requiring dialysis or transplantation.

The incidence figure understates the total addressable market. Because primary IgA nephropathy is chronic and slowly progressive, the prevalent patient pool at any point is considerably larger than the incident cohort. Patients typically live with the disease for decades, meaning cumulative treatment opportunity extends well beyond the newly diagnosed group each year.

The United States alone represents a substantial share of the accessible commercial market because reimbursement structures generally support innovative therapies with strong clinical evidence. Fabhalta’s traditional approval label positions the therapy for use throughout the treatment journey, from early disease with proteinuria to more advanced stages with measurable eGFR decline.

Physicians have historically been limited to angiotensin-blocking therapies and, more recently, sparsentan and budesonide-based approaches. The addition of complement, endothelin and B-cell mechanisms expands the toolkit but also creates a competitive market in which no single therapy is likely to dominate.

Fabhalta enters that market with the strongest label but the highest initiation burden. Novartis must convert its regulatory advantage into physician preference before ORIGIN 3 eGFR data and other pipeline readouts change the competitive frame.

Why does the Fabhalta approval arrive at a strategically important moment for Novartis?

The timing of the FDA decision is not coincidental to Novartis’s broader financial narrative. The company is scheduled to release its second-quarter 2026 results on 18 July 2026, one day after the Fabhalta traditional approval was announced. Consensus expectations coming into the quarter had reflected a projected 9.1 percent decline in earnings per share year-on-year, driven in part by patent expirations affecting the cardiovascular drug Entresto.

Novartis has been working to offset those pressures through a portfolio of newer specialty launches and targeted acquisitions. The company agreed to acquire Myricx Bio for up to 1.5 billion dollars in early July to strengthen its oncology pipeline, and continues to invest in kidney, immunology and neuroscience assets.

Fabhalta is one of the products management has consistently highlighted as a driver of longer-term growth. A traditional approval label meaningfully strengthens the commercial case for that positioning. Prescribers, payers and investors can now assess Fabhalta on the basis of confirmed disease-modifying data rather than an accelerated proteinuria claim.

The share price context is also relevant. Novartis stock traded around 150 to 152 dollars in New York during mid-July 2026, within a 52-week range of approximately 112 to 170 dollars. The all-time closing high of 163.64 dollars was reached on 27 February 2026. The stock remains a component of major healthcare and dividend indices, with a market capitalisation of roughly 290 billion dollars.

The Fabhalta decision is unlikely to reverse near-term earnings pressure by itself. Its value lies in reinforcing the medium-term revenue narrative that management will need to defend during the Q2 earnings call.

What remains unresolved and what would strengthen or weaken the Fabhalta thesis from here?

Several important questions remain open even after the traditional approval. Long-term data on hard kidney outcomes, such as progression to end-stage kidney disease, dialysis initiation or transplantation, will develop only over years. The strength of the current label depends on eGFR slope as a validated surrogate, and any future regulatory or clinical guideline changes to that framework could affect the perceived value of the approval.

Real-world uptake will be the next commercially observable proof point. Novartis has not disclosed detailed IgA nephropathy sales for Fabhalta separately in prior quarters, and investors will look for updated commentary during the Q2 2026 results release. Meaningful acceleration in prescriptions, particularly in nephrology practices that also manage complement-inhibitor patients in other indications, would validate the commercial thesis.

Vera Therapeutics’s ORIGIN 3 eGFR readout in the third quarter of 2026 is the most immediate competitive risk. A strong result would allow Trutakna to move towards full approval in 2027 and neutralise part of Fabhalta’s current label advantage. A weak or ambiguous result would extend the Novartis lead materially.

The pace of Vanrafia uptake and clinical development progress on zigakibart will also affect the durability of the franchise. If Novartis can position the three therapies as complementary components of a single patient journey, the portfolio approach becomes harder for single-asset competitors to disrupt.

The commercial thesis would weaken if REMS-related friction slows Fabhalta initiation, if competitor therapies deliver comparable eGFR data at simpler operational cost, or if payer restrictions offset the value of the traditional approval. It would strengthen if Novartis converts the current regulatory advantage into measurable market share, defends the portfolio against the ORIGIN 3 readout, and delivers the additional pipeline data on which the medium-term IgA nephropathy narrative depends.

What are the key takeaways from the Novartis Fabhalta FDA traditional approval decision?

• Novartis has received FDA traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary IgA nephropathy at risk of disease progression.
• The traditional approval upgrades an August 2024 accelerated approval for the reduction of proteinuria, giving Fabhalta the first full disease-modifying complement-inhibitor label in primary IgA nephropathy.
• APPLAUSE-IgAN Phase III data showed Fabhalta produced annualised eGFR decline of 3.0 millilitres per minute per 1.73 square metres per year compared with 5.7 for placebo, equivalent to a 48 percent slower rate of kidney function decline.
• Proteinuria reductions were observed as early as two weeks and sustained through the two-year study period.
• Fabhalta remains subject to a Risk Evaluation and Mitigation Strategy programme because of the risk of serious infections from encapsulated bacteria, and requires vaccinations before initiation.
• Vera Therapeutics Trutakna (atacicept-vymj) received FDA accelerated approval for proteinuria reduction in primary IgA nephropathy on 7 July 2026, ten days before the Fabhalta decision, and still requires eGFR data for full approval.
• Novartis operates a broader IgA nephropathy portfolio that also includes Vanrafia (atrasentan) and investigational zigakibart, positioning the company for combination or sequential treatment approaches.
• Nearly 100 percent of United States Fabhalta patients pay 10 dollars or less per month through Novartis access programmes, addressing a historical barrier to complement-inhibitor uptake.
• The approval landed one day before the scheduled 18 July 2026 Novartis Q2 2026 earnings release, reinforcing the medium-term specialty growth narrative during a period of Entresto patent-related pressure.
• The next competitive test will be Vera Therapeutics’s ORIGIN 3 eGFR readout in the third quarter of 2026, followed by a supplemental Biologics License Application for Trutakna full approval expected in the fourth quarter.